Envision Healthcare Securities Litigation

March 21, 2024. The Court in the Envision Healthcare Corporation securities matter (Middle District of Tennessee) approved a class action settlement in the amount of $177.5 million. Plaintiffs alleged that Envision artificially inflated its earnings through out-of-network billing, illegal upcoding, and inflated facility spending. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided […]

Aegean Marine Petroleum Network Securities Litigation

October 19, 2023. The Court in the Aegean Marine Petroleum Network securities matter (Southern District of New York) approved a $11.9 million settlement between Aegean shareholders and individual defendants. Previously, PWC Greece and Deloitte Greece agreed to pay $14.9 million each to settle with Aegean shareholders. Plaintiffs alleged that the individual defendants had taken part […]

Grupo Televisa Securities Litigation 

April 20, 2023. The Parties agreed to and the Court approved a $95 million settlement in a class action lawsuit filed against Grupo Televisa. Plaintiffs alleged that Grupo Televisa paid bribes to Fédération Internationale de Football Association (“FIFA”) executives for World Cup broadcast rights. According to Plaintiffs, the concealed scheme artificially inflated the market price […]

Synchrony Financial Securities Litigation

April 12, 2023. The Parties agreed to and the Court approved a $34 million settlement in a class action securities case involving Synchrony Financial. Plaintiffs alleged that Synchrony misrepresented the quality of its loan portfolio and underwriting practices. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert analysis and testimony on market […]

Cardinal Health Securities Litigation 

April 4, 2023. The Parties agreed to and the Court approved a $109 million settlement in a class action securities litigation brought against Cardinal Health. Plaintiffs alleged that Cardinal failed to disclose inventory and supply chain issues at Cordis Corp., an operating unit the company acquired. Professor Steven Feinstein of Babson College and Crowninshield Financial […]

Splunk Securities Litigation 

February 27, 2023. The parties in the Splunk Inc. Securities Litigation (Northern District of California) agreed to a $30 million class action settlement. Plaintiffs alleged that Splunk had falsely claimed that the company was on track to produce $1 billion in operating cash flow by 2023. Poor quarterly financial results that allegedly revealed previously concealed […]

Inovio Pharmaceuticals Securities Litigation 

January 18, 2023. The Parties agreed to and the Court approved a $44 million settlement in a class action lawsuit filed against Inovio Pharmaceuticals. Plaintiffs alleged that the Company made misleading statements about its ability to quickly produce an effective Covid-19 vaccine. According to Plaintiffs, the misrepresentation inflated the Company’s stock price and caused investor […]

AmTrust Securities Litigation

November 16, 2022. The Court in the Amtrust securities matter (Southern District of New York) approved a class action settlement in the amount of $13 million. Plaintiff alleged that defendants misrepresented and omitted material facts concerning the future of the company’s preferred shares, including the shares’ continued listing on the NYSE. Professor Steven Feinstein of […]

AmTrust Financial Services Securities Litigation

November 16, 2022. The Parties agreed to and the Court approved a $13 million settlement in a class action securities lawsuit involving AmTrust Financial Services. Plaintiffs alleged that the company mislead investors by telling them the that the Company’s preferred shares would continue to be listed on the New York Stock Exchange after a planned […]

Innocoll Securities Litigation

October 28, 2022. The Court in the Innocoll securities matter (Eastern District of Pennsylvania) approved a class action settlement in the amount of $2.755 million. Plaintiff alleged that defendants concealed risks relating to the likelihood that the company’s pain management drug XaraColl would receive FDA approval. Plaintiffs retained Crowninshield Financial Research to provide expert analysis […]